uniQure’s Promising Developments and Regulatory Progress Drive Buy Rating

William Blair analyst Sami Corwin has maintained their bullish stance on QURE stock, giving a Buy rating yesterday.

Sami Corwin has given his Buy rating due to a combination of factors related to uniQure’s promising developments and regulatory progress. The completion of Type B meetings with the FDA regarding AMT-130’s CMC requirements and pivotal statistical analysis plan is a significant milestone, especially with the therapy receiving a breakthrough-therapy designation. This designation indicates the potential of AMT-130 to address unmet medical needs in Huntington’s disease.
Moreover, the initial safety data from the cohort of Huntington’s disease patients treated with AMT-130 shows a tolerable safety profile, with no treatment-related serious adverse events. The company’s strategic decision to opt for a perioperative course of steroids further supports the therapy’s safety management. Additionally, upcoming updates on regulatory submissions and clinical data from ongoing trials, including AMT-260 and AMT-191, highlight uniQure’s robust pipeline and potential for future growth.

In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $70.00 price target.

Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of QURE in relation to earlier this year.